Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

Neupro

This page shows the latest Neupro news and features for those working in and with pharma, biotech and healthcare.

UCB boosted by core medicines growth

UCB boosted by core medicines growth

drug Neupro (rotigotine) having combined net sales of 1.46bn, a growth of 24% on 2013. ... Sales of Vimpat increased by 15% to 471m, while Neupro revenue rose 10% to 200m, although these two grew less than analysts had predicted.

Latest news

  • UCB names Jean-Christophe Tellier as Doliveux's successor UCB names Jean-Christophe Tellier as Doliveux's successor

    These include already-marketed drugs such as epilepsy therapy Vimpat (lacosamide) and Neupro (rotigotine) for Parkinson's disease and restless legs syndrome (RLS), which are both growing quickly, as well as

  • UCB files Vimpat patent claims against 15 companies UCB files Vimpat patent claims against 15 companies

    Along with other recent launches like Cimzia (certolizumab pegol) for rheumatoid arthritis and Crohn's disease and the Neupro (rotigotine) patch for Parkinson's disease, Vimpat has helped UCB weather the ... During 2012, UCB reached the 'crossover point'

  • Saatchi & Saatchi create Spanish restless legs syndrome campaign Saatchi & Saatchi create Spanish restless legs syndrome campaign

    And in May this year, new data was published showing Neupro reduced total nocturnal systolic blood pressure (NSBP) elevations in people with RLS. ... Neupro provides a novel way of treating RLS and PD through continuous transdermal dopaminergic delivery.

  • UCB says new medicines drive growth in 2012 UCB says new medicines drive growth in 2012

    UCB's Neupro (rotigotine) patch for Parkinson's disease also did well, rising 40 per cent to 133m, although generic erosion continue to affect epilepsy drug Keppra (levetiracetam), which fell 13 ... During 2012, UCB reached the 'crossover point' where

  • Product updates from Japan

    dentistry. Otsuka Pharmaceutical has been given a green light in Japan for Neupro Patch (rotigotine) as a treatment for Parkinson's disease and restless legs syndrome.

More from news
Approximately 1 fully matching, plus 16 partially matching documents found.

Latest Intelligence

  • Pharma deals during November 2013 Pharma deals during November 2013

    Certainly the good performances from key products such as Cimzia, Vimpat and Neupro may well appeal to those companies feeling a little pipeline bereft.

  • VIDEO interview: Neil Weir, UCB VIDEO interview: Neil Weir, UCB

    epilepsy; and Neupro (rotigotine) for Parkinson's disease and restless legs syndrome. ... As for the future of the company, Dr Weir is pleased with the success of Cimzia, Vimpat and Neupro, allowing the company to reinvest in its pipeline, and embrace an

  • Interview with Roch Doliveux, UCB Interview with Roch Doliveux, UCB

    UCB is focused on the neurology and immunology therapy areas. We have just launched three new medicines: Cimzia for rheumatoid arthritis and Crohn's disease; Vimpat for epilepsy and Neupro for ... Now, growth will be driven by new products such as Cimizia

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Subscribe to our email news alerts

PMHub

Add my company
Accession

Accession was a born from a passion and a vision. A passion to harness the power of market access to...

Latest intelligence

Rare diseases: not so rare after all
The brave new world addressing rare diseases – a way ahead to better and more inclusive treatment...
Webinar: Evolving Patient Journeys - How to generate deeper insights in a changing healthcare landscape
Register now for part one in a series, Evolving Patient Journeys, in which our experts look at the main ways in which the patient journey has evolved in recent years....
DIGITAL EXPERIENCES: LEARNINGS FROM OUTSIDE PHARMA
It’s long been the case that pharma lags behind other industries when it comes to digital adoption and engagement. So, what can we learn from these other industries, and how...

Quick links